Hospitals are itching for a share of the Mylan settlement over Medicaid rebates
(By Ed Silverman for STAT) More than 1,200 hospitals around the country want to know if they were overcharged by
Read More
Part D/Prescription Drugs
The backlash over high drug prices is hitting pharma where it hurts
(By Meghana Keshavan for STAT) The simmering public outrage over drug prices finally seems to be catching up to the
Read MoreHow Do We Lower Medicare Drug Costs
Health policy experts all agree something needs to be done to lower Medicare drug costs but none agree on how
Read MoreCalifornians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?
(By Ed Silverman for STAT) As Americans grapple with the rising cost of medicines, a contentious ballot measure1 in California
Read MoreMany Medicare Beneficiaries Not Reviewing Options
In a new Walgreens survey reveals even though drug costs are a top concern for Medicare beneficiaries, they are not
Read MoreGenetic testing fumbles, revealing ‘dark side’ of precision medicine
(By Sharon Begley for STAT) Enthusiasm for precision medicine1, from the White House2 down to everyday physicians, is at an all-time high.
Read MoreOpen Enrollment–Some Thoughts to Help You get Prepared
Now–right now–is the time to take stock in your situation while you still have time, and to get prepared to
Read MoreMedicare Bars New ‘Seamless Conversion’ Efforts For Some Seniors
(By Susan Jaffe for Kaiser Health News) The federal government is temporarily blocking more health insurance companies from automatically moving
Read MoreFTC seeks review of a court ruling on generic drug competition
(By Ed Silverman for STAT) The US Federal Trade Commission has once again waded into a closely watched legal battle
Read MoreAn EpiPen alternative is about to return to your local pharmacy
(By Ed Silverman for STAT) The controversial EpiPen device is about to get still more competition. A company that now
Read More